The Israeli Fintech Index Q1 2026
The Israeli fintech cohort entered Q1 2026 substantially repriced and consolidated. Inside the public-equity roster, the 2025 M&A reset (Melio, Next Insurance), the mid-market private layer, and the Q1 2026 funding picture.
The Israeli fintech cohort entered Q1 2026 as one of the most repriced — and most consolidated — segments of the broader Israeli technology universe. Per IVC-LeumiTech, Startup Nation Central, and trade-press coverage in Calcalist, Globes, Bloomberg, and TechCrunch, the quarter marked the first full reading of a public-equity cohort that had been substantially reset between 2022 and 2025, alongside a private-stage layer compressed by acquisition rather than IPO. The composite picture: lower multiples, more strategic exits, fewer mid-cap independents, and a narrower but more profitable public roster.
The public-equity roster
The Israeli-founded fintech public-equity cohort going into Q1 2026 carries seven principal listings on US exchanges: eToro (NASDAQ: ETOR), Pagaya Technologies (NASDAQ: PGY), Payoneer (NASDAQ: PAYO), Riskified (NYSE: RSKD), Lemonade (NYSE: LMND), Hippo Holdings (NYSE: HIPO), and Nayax (TASE and NASDAQ: NYAX). All seven are Israeli-founded; six are Israeli-headquartered or maintain primary R&D in Israel.
eToro, co-founded by Yoni Assia, reopened the cohort in May 2025 at a $4.3 billion Nasdaq IPO valuation — the first major Israeli fintech listing since 2021. Pagaya, by contrast, completed its own institutional inflection. Per the company's May 7, 2025 results, the AI-driven consumer credit underwriter posted its first-ever quarter of GAAP profitability: net income attributable to shareholders of $8 million in Q1 2025, a $29 million year-over-year swing from the $21 million loss in Q1 2024, on record revenue and other income of $290 million and record adjusted EBITDA of $80 million. Pagaya followed with a second consecutive profitable quarter in Q2 2025 ($17 million net income, $326 million revenue) and raised full-year guidance. Payoneer and Riskified entered Q1 2026 trading well below their 2021 IPO peaks but with margins stabilized through cost discipline. Lemonade and Hippo, the two insurtech listings, remain the most contested public positions in the cohort, with loss-ratio improvement diverging across the two operators.
The 2025 M&A reset
The defining Q1 2026 read on the broader fintech cohort is structural, not cyclical: the floor in this cycle was reached through acquisition, not endurance.
Two transactions anchor the pattern.
Melio — the B2B payments operator founded in 2018 by Matan Bar and Ilan Atias, New York-headquartered with roughly 400 of its 600 employees in Israel — was acquired by New Zealand-founded, ASX-listed accounting platform Xero (ASX: XRO) under a binding agreement announced June 25, 2025. Upfront consideration was $2.5 billion in cash and equity, with up to a further $500 million in contingent consideration, deferrals and rollovers payable to Melio employees over three years — an enterprise value of up to $3 billion. Melio processed approximately $30 billion in annual payment volume for around 80,000 small-business customers, on annualized revenue of $187 million. Its last private round, a $150 million Series E led by Fiserv in October 2024, valued it at roughly $2 billion — itself a material markdown from the prior round.
Next Insurance — the small-business insurtech founded in 2016 by Guy Goldstein, Nissim Tapiro and Alon Huri — was acquired by Germany's Munich Re through its ERGO unit for $2.6 billion in cash, announced March 20, 2025 and closed in Q3 2025. Munich Re purchased the 71% of shares it did not already hold. Next generated a $548 million top line in 2024 across more than 600,000 customers, and had last been valued at $2.5 billion in late 2023 — down from $4 billion in 2021.
Both transactions resolved post-2021 down-round trajectories through strategic acquisition by mature non-Israeli operators, at multiples materially below 2021 private-round valuations. The institutional read: the post-2022 fintech reset compressed mid-stage private valuations to levels at which acquisition by mature insurance and accounting operators became the structural exit, replacing public-market endurance as the cohort's primary path.
The mid-market private layer
Below the public roster, the Israeli mid-market fintech layer continued to consolidate around a smaller number of identifiable category leaders: Tipalti (payment automation), Earnix (pricing and rating), Personetics (consumer banking analytics), Capitolis (capital markets infrastructure), Unit (banking-as-a-service), ThetaRay (financial-crime detection), and BioCatch (behavioral biometrics).
Per IVC-LeumiTech Q1 2026 data, this mid-market layer attracted the majority of the quarter's Israeli fintech private-stage capital. The pattern: fewer rounds, larger checks, deeper concentration in operators with demonstrated enterprise customer traction. Seed and pre-seed activity in the fintech category compressed materially against 2021–2022 baselines.
The Q1 2026 funding picture
Specific Q1 2026 financings disclosed in trade-press coverage cluster around two themes. The first — AI-driven underwriting and analytics — anchored by Pagaya's continued partner-bank expansion, Personetics's ongoing institutional deployments, and BioCatch's behavioral-biometrics traction. The second — B2B payments and embedded finance — anchored by Tipalti and Unit, both operating at scale across non-Israeli customer bases.
Notably absent from the Q1 2026 disclosed-financing roster: late-stage consumer-facing Israeli fintech operators of the 2020–2021 era. The retail-trading, neobank, and SMB-payments categories that defined that period are now substantially consolidated, public, or acquired.
The structural read
The Q1 2026 Israeli fintech index reflects a cohort that has resolved most of its post-2022 dislocations. Public-equity multiples have stabilized at lower but sustainable levels. Mid-stage privates have either consolidated through acquisition or compressed to a defensible institutional core. The seed layer has contracted.
The next inflection point: whether the public cohort can produce a second-wave IPO beyond eToro — a question dependent on the broader US public-markets reopening for technology and on the reference environment set by Google's completed $32 billion acquisition of Wiz in March 2026, which removed the most anticipated Israeli security listing of the decade from the IPO market entirely.
Frequently asked questions
Which Israeli fintech companies are publicly listed?
Seven principal Israeli-founded fintech listings: eToro (NASDAQ: ETOR), Pagaya Technologies (NASDAQ: PGY), Payoneer (NASDAQ: PAYO), Riskified (NYSE: RSKD), Lemonade (NYSE: LMND), Hippo Holdings (NYSE: HIPO), and Nayax (dual-listed on TASE and NASDAQ: NYAX).
What was the largest Israeli fintech exit of 2025?
Xero's acquisition of Melio, announced June 25, 2025, at $2.5 billion upfront and up to $3 billion including contingent consideration. Munich Re's $2.6 billion all-cash acquisition of Next Insurance, announced March 20, 2025, was comparable in headline value.
Is Pagaya profitable?
Yes. Pagaya reported its first GAAP-profitable quarter in Q1 2025 with $8 million of net income attributable to shareholders, and a second consecutive profitable quarter in Q2 2025 with $17 million.
Why did Israeli fintech consolidate through M&A rather than IPOs?
The post-2022 reset compressed mid-stage private valuations below their 2021 marks. At those levels, acquisition by mature global insurance and accounting operators cleared at better terms than public-market endurance — the pattern visible in both Melio and Next Insurance, each of which had taken a down round before the sale.
Source data: IVC-LeumiTech Q1 2026 capital data; Startup Nation Central; SEC filings and company disclosures of cohort issuers (Pagaya Q1 and Q2 2025 results); Xero ASX announcement of June 25, 2025; Munich Re announcement of March 20, 2025; coverage in Calcalist, Globes, Bloomberg, Reuters, TechCrunch. Cohort data current as of Q1 2026.
Related on Olam — Israeli public equities and capital markets
- The Israeli ADR Universe on NASDAQ and NYSE
- The TASE 35: Sector Weight, Composition, and the Israeli Large-Cap Public-Equity Architecture
- The Dual-Listing Model: NASDAQ-TASE and the PANW Precedent
- The Convertible-Bond Track: Wix, Check Point, and Mature-Stage Capital
- TASE Foreign Institutional Ownership
- ICL Group: The Dead Sea Chemicals Position
- Playtika and the Israeli Public Gaming Position
- Israeli Fintech and Public Markets: The Complete Map
- The Builders — canonical profiles of the founders behind the cohort
